CELLDEX THERAPEUTICS INC (CLDX) Stock Price, Quote, News and Overview
NASDAQ:CLDX - Nasdaq - US15117B2025 - Common Stock - Currency: USD
CLDX Quote, Performance and Key Statistics
18.94
+0.64 (+3.5%)
The current stock price of CLDX is 18.94 USD. In the past month the price decreased by -3.56%. In the past year, price decreased by -47.82%.
CLDX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.81 | 301.01B | ||
| AMGN | AMGEN INC | 13.81 | 147.14B | ||
| GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
| ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
| NTRA | NATERA INC | N/A | 19.23B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
| BIIB | BIOGEN INC | 7.07 | 17.05B |
Related stock screener links
About CLDX
Company Profile
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 186 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Company Info
CELLDEX THERAPEUTICS INC
53 Frontage Road, Suite 220
Hampton NEW JERSEY 08827 US
CEO: Anthony S. Marucci
Employees: 160
Company Website: https://celldex.com/
Investor Relations: https://ir.celldex.com
Phone: 19082007500
CELLDEX THERAPEUTICS INC / CLDX FAQ
What is the stock price of CELLDEX THERAPEUTICS INC today?
The current stock price of CLDX is 18.94 USD. The price increased by 3.5% in the last trading session.
What is the ticker symbol for CELLDEX THERAPEUTICS INC stock?
The exchange symbol of CELLDEX THERAPEUTICS INC is CLDX and it is listed on the Nasdaq exchange.
On which exchange is CLDX stock listed?
CLDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CELLDEX THERAPEUTICS INC stock?
20 analysts have analysed CLDX and the average price target is 63.33 USD. This implies a price increase of 234.35% is expected in the next year compared to the current price of 18.94. Check the CELLDEX THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CELLDEX THERAPEUTICS INC worth?
CELLDEX THERAPEUTICS INC (CLDX) has a market capitalization of 1.26B USD. This makes CLDX a Small Cap stock.
How many employees does CELLDEX THERAPEUTICS INC have?
CELLDEX THERAPEUTICS INC (CLDX) currently has 160 employees.
What are the support and resistance levels for CELLDEX THERAPEUTICS INC (CLDX) stock?
CELLDEX THERAPEUTICS INC (CLDX) has a resistance level at 19.78. Check the full technical report for a detailed analysis of CLDX support and resistance levels.
Is CELLDEX THERAPEUTICS INC (CLDX) expected to grow?
The Revenue of CELLDEX THERAPEUTICS INC (CLDX) is expected to decline by -41.63% in the next year. Check the estimates tab for more information on the CLDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CELLDEX THERAPEUTICS INC (CLDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLDX, evaluating the profitability, health, valuation and growth aspects
- CELLDEX THERAPEUTICS INC (CLDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CELLDEX THERAPEUTICS INC (CLDX) Sales and EPS estimates to see what analysts future expectations are.
- CELLDEX THERAPEUTICS INC (CLDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CELLDEX THERAPEUTICS INC (CLDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CELLDEX THERAPEUTICS INC (CLDX) Stock Chart to make your own analysis
- CELLDEX THERAPEUTICS INC (CLDX) Latest news and press-releases to stay up to date.
Does CELLDEX THERAPEUTICS INC (CLDX) stock pay dividends?
CLDX does not pay a dividend.
When does CELLDEX THERAPEUTICS INC (CLDX) report earnings?
CELLDEX THERAPEUTICS INC (CLDX) will report earnings on 2025-05-01.
What is the Price/Earnings (PE) ratio of CELLDEX THERAPEUTICS INC (CLDX)?
CELLDEX THERAPEUTICS INC (CLDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.45).
What is the Short Interest ratio of CELLDEX THERAPEUTICS INC (CLDX) stock?
The outstanding short interest for CELLDEX THERAPEUTICS INC (CLDX) is 13.42% of its float. Check the ownership tab for more information on the CLDX short interest.
CLDX Technical Analysis
CLDX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CLDX. While CLDX has a great health rating, there are worries on its profitability.
CLDX Financial Highlights
Over the last trailing twelve months CLDX reported a non-GAAP Earnings per Share(EPS) of -2.45. The EPS increased by 15.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.92% | ||
| ROE | -21.13% | ||
| Debt/Equity | 0 |
CLDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to CLDX. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of -36.45% and a revenue growth -41.63% for CLDX